Yifan Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Yifan Pharmaceutical Co., Ltd. (SZ: 002019) is an innovative R&D and production enterprise focused on the field of medicine and health. It is committed to combining classic discovery with classical innovation, conducting scientific verification of possible solutions, and contributing updated professional strength to the global pharmaceutical and health industry. We have established five independent research centers in San Francisco, Shanghai, Beijing, Hangzhou, and Hefei, focusing on the four core businesses of macromolecules, small molecules, synthetic biology, and characteristic traditional Chinese medicine. We have fully collaborated with high-quality innovative resources at home and abroad, continuously increased our innovative research and development efforts, and initially formed a differentiated, diversified, and competitive product research and development pipeline that meets clinical needs and has commercial value. We have nearly 50 products under research, covering innovative drugs, biomimetic drugs Genetics, traditional Chinese patent medicines and simple preparations, synthetic biology, etc. We have established an innovative drug development platform based on eukaryotic and prokaryotic expression systems, focusing on the fields of blood tumors, body inflammation, endocrine/metabolic, dermatology, gynecology and pediatrics. We have integrated research and production technology platforms for oral sustained-release formulations, micronized suspensions, injection micelles, high-end complex liquid formulations, and other fields; And around the fields of characteristic medical raw materials such as vitamins, antiviral drugs, cytotoxic drugs, and contrast agents, we have established a research and development technology platform for medical raw materials such as continuous flow reaction, peptide solid-phase synthesis, and high activity cytotoxicity, focusing on building an innovative research and development system for the entire industry chain from medical raw materials, characteristic intermediates, to pharmaceutical preparations; In addition, we actively collaborate on projects with well-known synthetic biology companies both domestically and internationally, mastering a complete and efficient industrial amplification technology system for synthetic biology, and continuously building cost and scale advantages with disruptive technologies. With forward-looking strategic planning and excellent resource integration capabilities, we have established more than ten formulation production bases at home and abroad that comply with cGMP management standards such as NMPA, FDA, and EMA. We have more than 100 production lines for each formulation, and are equipped with advanced pharmaceutical production facilities, quality, and laboratory management systems. With the highest industry standards and international standards, we have fully formed an industrial supply chain system that synchronizes internal supply with external CMO, Support the company's large-scale and commercial production of products in sales and research. In order to enhance the accessibility of value drugs to global patients, enable patients in every corner to receive reliable and affordable treatment drugs, and regain healthy lives, we actively promote the construction of a comprehensive global commercial network, allowing domestic high-quality drugs to go global, and introducing overseas high-quality drugs. At present, we have provided commercial services in over 40 countries and regions in Southeast Asia, including Singapore, South Korea, Italy, China, Germany, the United States, and Europe and America. Facing the future, Yifan adheres to a calm mindset, critical vision, and pioneering spirit, upholds its original aspiration, steadily grows, and strives to eliminate human diseases. |
| Headquarter | Hangzhou |
| Establish Date | 11/10/2000 |
| Listed Code | 002019.SZ |
| Listed Date | 7/13/2004 |
| Chairman | Cheng Xianfeng. |
| CEO | Cheng Xianfeng. |
| Website | www.yifanyy.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
